Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Solid Tumor 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Muscle Invasive Bladder Cancer 1

Interventions

atezolizumab 2Etoposide 2Carboplatin 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Cancer Extensive Stage × tislelizumab × Clear all
NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡